Extrusion firm Plastifab Industries Inc. is buying South Carolina injection molder Marchel Industries Inc. to broaden its geographic reach and manufacturing portfolio.
Plastifab, based in Saint-Laurent, Quebec, said the acquisition of Spartanburg, S.C.-based Marchel and its 36,000-square-foot factory will expand its offerings of custom manufacturing capabilities and give it a presence in the U.S.
The acquisition was announced March 15 by Plastifab's private equity owners, Regimen Equity Partners in Vancouver, B.C.
"The capabilities that Marchel exhibits allows us to follow our mission by strengthening our offering through Marchel's injection molding capabilities, providing another layer of custom solutions to our valued customers," said Ryan Antoniadis, Plastifab president and CEO.
Regimen bought Plastifab in 2016.
"The acquisition of Marchel represents another level of growth for Plastifab, instantaneously diversifying Plastifab's portfolio of services while simultaneously growing into the United States and different end markets," said Gerry Bellerive, Regimen's managing director.
Plastifab ranked 118th in the 2022 Plastics News ranking of North American pipe, profile and tubing extruders, with an estimated $15 million in sales, 60 employees and 45 extrusion lines. It works in a variety of industrial and commercial end markets.
The companies said Marchel would continue to be led day-to-day by Matt Pitts, son of company founder Gene Pitts.
"Plastifab brings to the table tremendous capabilities, giving Marchel the ability to scale alongside Plastifab," said Matt Pitts. "We are enthusiastic to be joining forces with Plastifab and genuinely believe they are the ideal new partner for Marchel."
Marchel serves customers in original equipment manufacturing, medical, government, automotive and industrial applications. It has an in-house toolshop, as well as capabilities in precision machining, electrical discharge machining, plastic design, prototyping and dimensional analysis.